The effect of mosapride citrate on constipation in patients with diabetes

Diabetes Research and Clinical Practice

Volumn 87, Issue 1, 2010, Pages 27-32

  Ueno, Naohiko ^a   Inui, Akio ^b   Satoh, Yoshiko ^a  

^a Kobe Seaside Hospital   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

5 HT4 agonist; Constipation; Diabetes mellitus; Diabetic neuropathy; Mosapride citrate

Indexed keywords

DOMPERIDONE; MOSAPRIDE CITRATE;

ABDOMINAL PAIN; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIARRHEA; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEARTBURN; HUMAN; INDIGESTION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

AGED; BENZAMIDES; BLOOD GLUCOSE; BODY MASS INDEX; CONSTIPATION; DEFECATION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; SEROTONIN AGONISTS;

EID: 73749084717     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.09.024     Document Type: Article

References (37)

1. Goyal R.K., and Spiro H.M. Gastrointestinal manifestations of diabetes mellitus. Med. Clin. North Am. 55 (1971) 1031-1044
2. Keshavarzian A., and Iber F.L. Intestinal transit in insulin-requiring diabetics. Am. J. Gastroenterol. 81 (1986) 257-260
3. Feldman M., and Schiller L.R. Disorders of gastrointestinal motility associated with diabetes mellitus. Ann. Intern. Med. 98 (1983) 378-384
4. Brown C.K., and Khanderia U. Use of metoclopramide, domperidone, and cisapride in the management of diabetic gastroparesis. Clin. Pharm. 9 (1990) 357-365
5. Frazee L.A., and Mauro L.S. Erythromycin in the treatment of diabetic gastroparesis. Am. J. Ther. 1 (1994) 287-295
6. Brogden R.N., Carmine A.A., Heel R.C., Speight T.M., and Avery G.S. Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 24 (1982) 360-400
7. Kii Y., Nakatsuji K., Nose I., Yabuuchi M., Mizuki Y., and Ito T. Effects of 5-HT(4) receptor agonists, cisapride and mosapride citrate on electrocardiogram in anaesthetized rats and guinea-pigs and conscious cats. Pharmacol. Toxicol. 89 (2001) 96-103
8. Gershon M.D. Review article: serotonin receptors and transporters-roles in normal and abnormal gastrointestinal motility. Aliment. Pharmacol. Ther. Suppl. 7 (2004) 3-14
9. Baxter G.S., Craig D.A., and Clarke D.E. 5-Hydroxytryptamine4 receptors mediate relaxation of the rat oesophageal tunica muscularis mucosae. Naunyn Schmiedebergs Arch. Pharmacol. 343 (1991) 439-446
10. Mader R., Kocher T., Haier J., Wieczorek G., Pfannkuche H.J., and Ito M. Investigation of serotonin type 4 receptor expression in human and non-human primate gastrointestinal samples. Eur. J. Gastroenterol. Hepatol. 18 (2006) 945-950
11. Ruth M., Finizia C., Cange L., and Lundell L. The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease. Eur. J. Gastroenterol. Hepatol. 15 (2003) 1115-1121
12. Mizuta Y., Shikuwa S., Isomoto H., Mishima R., Akazawa Y., Masuda J., et al. Recent insights into digestive motility in functional dyspepsia. J. Gastroenterol. 41 (2006) 1025-1040
13. Yoshida N., Omoya H., Oka M., Furukawa K., Ito T., and Karasawa T. AS-4370, a novel gastrokinetic agent free of dopamine D2 receptor antagonist properties. Arch. Int. Pharmacodyn. Ther. 300 (1989) 51-67
14. Asakawa H., Hayashi I., Fukui T., and Tokunaga K. Effect of mosapride on glycemic control and gastric emptying in type 2 diabetes mellitus patients with gastropathy. Diabetes Res. Clin. Pract. 61 (2003) 175-182
15. Talley N.J. Serotoninergic neuroenteric modulators. Lancet 358 (2001) 2061-2068
16. Liu Z., Sakakibara R., and Odaka T. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in Parkinsonian patients. Mov. Disord. 20 (2005) 680-686
17. Ueno N., Inui A., Asakawa A., Takao F., Komatsu Y., Kotani K.A., et al. Mosapride, a 5HT-4 receptor agonist, improves insulin sensitivity and glycaemic control in patients with Type II diabetes mellitus. Diabetologia 45 (2002) 792-797
18. McLean P.G., and Coupar I.M. Stimulation of cyclic AMP formation in the circular smooth muscle of human colon by activation of 5-HT4-like receptors. Br. J. Pharmacol. 117 (1996) 238-239
19. Sakurai-Yamashita Y., Yamashita K., Yoshimura M., and Taniyama K. Differential localization of 5-hydroxytryptamine3 and 5-hydroxytryptamine4 receptors in the human rectum. Life Sci. 66 (2000) 31-34
20. Longo W.E., and Vernava III A.M. Prokinetic agents for lower gastrointestinal motility disorders. Dis. Colon Rectum 36 (1993) 696-708
21. Svedlund J., Sjödin I., and Dotevall G. GSRS-a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig. Dis. Sci. 33 (1988) 129-134
22. Revicki D.A., Wood M., Wiklund I., and Crawley J. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual. Life Res. 7 (1998) 75-83
23. Hotta N., Akanuma Y., Kawamori R., Matsuoka K., Oka Y., Shichiri M., et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 29 (2006) 1538-1544
24. Pietraszek M.H., Takada Y., Takada A., Fujita M., Watanabe I., Taminato A., et al. Blood serotonergic mechanisms in type 2 (non-insulin-dependent) diabetes mellitus. Thromb. Res. 66 (1992) 765-774
25. Spångéus A., Kand M., and El-Salhy M. Gastrointestinal endocrine cells in an animal model for human type 2 diabetes. Dig. Dis. Sci. 44 (1999) 979-985
26. Inui A., Yoshikawa T., Nagai R., Yoshida N., and Ito T. A 5-HT4 receptor agonist, on colonic motility inconscious guinea pig. Jpn. J. Pharmacol. 90 (2002) 313-320
27. Kadowaki M., Wang X.O., Shimatani H., Yoneda S., and Takaki M. 5-HT4 receptor enhances the propulsive power of the peristaltic reflex in the rat distal colon. Auton. Neurosci. 99 (2002) 62-65
28. Edwards L.L., Quigley E.M., Harned R.K., Hofman R., and Pfeiffer R.F. Characterization of swallowing and defecation in Parkinson's disease. Am. J. Gastroenterol. 89 (1994) 15-25
29. Odaka T., Suzuki T., Seza A., Yamaguchi T., and Saisho H. Serotonin 5-HT4 receptor agonist (mosapride citrate). Nippon Rinsho. 64 (2006) 1491-1494
30. Shimatani H., Kojima Y., Kadowaki M., Nakagawa T., Fujii H., Nakajima Y., et al. A 5-HT4 agonist mosapride enhances rectorectal and rectoanal reflexes in guinea pigs. Am. J. Physiol. Gastrointest. Liver Physiol. 285 (2003) G389-395
31. Iida M., Ikeda M., Kishimoto M., Tsujino T., Kaneto H., Matsuhisa M., et al. Evaluation of gut motility in type II diabetes by the radiopaque marker method. J. Gastroenterol. Hepatol. 15 (2000) 381-385
32. Werth B., Meyer-Wyss B., Spinas G.A., Drewe J., and Beglinger C. Non-invasive assessment of gastrointestinal motility disorders in diabetic patients with and without cardiovascular signs of autonomic neuropathy. Gut 33 (1992) 1199-1203
33. Battle W.M., Snape Jr. W.J., and Alavi A. Colonic dysfunction in diabetes mellitus. Gastroenterology 79 (1980) 1217-1221
34. Gershon M.D., and Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132 (2007) 397-414
35. Gershon M.D. Serotonin and its implication for the management of irritable bowel syndrome. Rev. Gastroenterol. Disord. Suppl 2 (2003) S25-34
36. Poole D.P., Xu B., Koh S.L., Hunne B., Coupar I.M., Irving H.R., et al. Identification of neurons that express 5-hydroxytryptamine4 receptors in intestine. Cell Tissue Res. 325 (2006) 413-442
37. Taniyama K., Makimoto N., Furuichi A., Sakurai-Yamashita Y., Nagase Y., Kaibara M., et al. Functions of peripheral 5-hydroxytryptamine receptors, especially 5-hydroxytryptamine4 receptor, in gastrointestinal motility. J. Gastroenterol. 35 (2000) 575-582